BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16436698)

  • 1. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
    Wiederhold NP; Tam VH; Chi J; Prince RA; Kontoyiannis DP; Lewis RE
    Antimicrob Agents Chemother; 2006 Feb; 50(2):469-73. PubMed ID: 16436698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
    van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.
    Wiederhold NP; Kontoyiannis DP; Chi J; Prince RA; Tam VH; Lewis RE
    J Infect Dis; 2004 Oct; 190(8):1464-71. PubMed ID: 15378439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.
    Lestner JM; Howard SJ; Goodwin J; Gregson L; Majithiya J; Walsh TJ; Jensen GM; Hope WW
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3432-41. PubMed ID: 20439615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics.
    Groll AH; Gonzalez CE; Giri N; Kligys K; Love W; Peter J; Feuerstein E; Bacher J; Piscitelli SC; Walsh TJ
    J Antimicrob Chemother; 1999 Jan; 43(1):95-103. PubMed ID: 10381106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Prince RA; Chi J; Kontoyiannis DP
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
    Petraitis V; Petraitiene R; Groll AH; Bell A; Callender DP; Sein T; Schaufele RL; McMillian CL; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2898-905. PubMed ID: 9797223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
    Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
    J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
    Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.
    Petraitis V; Petraitiene R; Solomon J; Kelaher AM; Murray HA; Mya-San C; Bhandary AK; Sein T; Avila NA; Basevicius A; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1510-7. PubMed ID: 16569871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
    Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis.
    Petraitis V; Petraitiene R; Lin P; Calis K; Kelaher AM; Muray HA; Mya-San C; Mickiene D; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1642-5. PubMed ID: 15793161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.
    Andes D; Stamsted T; Conklin R
    Antimicrob Agents Chemother; 2001 Mar; 45(3):922-6. PubMed ID: 11181381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardization of an experimental murine model of invasive pulmonary aspergillosis.
    Sheppard DC; Graybill JR; Najvar LK; Chiang LY; Doedt T; Kirkpatrick WR; Bocanegra R; Vallor AC; Patterson TF; Filler SG
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3501-3. PubMed ID: 17005844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis.
    van de Sande WW; van Vianen W; ten Kate MT; Vissers J; Laurijsens J; Tavakol M; Rijnders BJ; Mathot RA; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1345-50. PubMed ID: 18195059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
    López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.
    Otsubo T; Maruyama K; Maesaki S; Miyazaki Y; Tanaka E; Takizawa T; Moribe K; Tomono K; Tashiro T; Kohno S
    Antimicrob Agents Chemother; 1998 Jan; 42(1):40-4. PubMed ID: 9449258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
    Manavathu EK; Cutright JL; Chandrasekar PH
    Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.